THURSDAY, APRIL 24, 2008
Gilead Symposium - NOON to 2 PM
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe, and Australia.
Follow your HAART: How faithful are we?
The goal of therapy for HIV/AIDS treatment is to suppress viral replication to undetectable levels. This is achievable with our current antiretroviral agents. The documented efficacy of antiretroviral therapy, however, isn’t always replicated in clinical practice. One of the key factors for reduced efficacy is non-adherence to the drug regimen in addition to our own perceptions of who should be treated and how.
Building on real life cases, this dynamic session will demystify perceptions of adherence across a spectrum of the patient population. A multi-disciplinary panel including a pharmacist, an HIV infectious disease specialist, a patient, and an activist will offer their perspectives on adherence and strategies that fit today’s reality. The Satellite promises to be thought provoking, interactive and insightful.
Dr. Chris Tsoukas – Chairperson
Chris Tsoukas, CM, MD, FRCP(C )
Professor of Medicine
Director, Division of Clinical Immunology and Allergy
McGill University
Dr. Mona Loutfy – Moderator
Mona Loutfy, MD, FRCPC, MPH
Research Scientist and Director
Women and HIV Research Program
Women's College Research Institute
Ms. Dawn Averitt Bridge - Panelist
Dr. Evan Collins Panelist
Ms. Rachel Therrien - Panelist
Dr. Mark Tyndall - Panelist
Abbott Laboratories Ltd - 4 PM to 5:15 PM
The benefits of viral suppression - beyond the individual
Referring to the findings from the Swiss cohort, Dr. Réjean Thomas will discuss the non-transmission of HIV when the viral load is undetectable.
Dr. Sharon Walmsley will review the role of protease inhibitors as 1st line therapy in achieving the goal of seeing the viral load becoming undetectable.
FRIDAY, APRIL 25, 2008
Bristol-Myers Squibb- 7 AM to 8:45 AM
The Science of ART:
Current Guidelines and Future Directions
Over the past two decades, a considerable amount of experience has been acquired on the use of antiretroviral therapies for the treatment of human immunodeficiency virus infection. With the accumulation of scientific data and the development of new drugs, there is an ongoing need to update treatment guidelines on the use of ART. Among the guidelines that will be reviewed and compared are those produced by the U.S. Department of Health and Human Services, the World Health Organization/International AIDS Society, and the provinces of Québec and British Columbia. The symposium will also summarize recent clinical trials and address the optimal use of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in clinical practice.
Jean-Guy Baril, MD - Chairperson
Clinique médicale du Quartier Latin, Montréal
Montréal, Québec
Cécile Tremblay, MD, FRCPC - Speaker
HUM – Hôtel Dieu Hospital
Montréal, Quebec
Mark Tyndall, MD, FRCPC - Speaker
St-Paul’s Hospital
Vancouver, British Columbia
GlaxoSmithKline Inc. in partnership with Shire Canada - 12:30 PM to 2 PM
Nucleoside Analogue Spring 2008 Update
Recently released clinical trial data on nucleoside analogue RTIs, including the combination tablet containing abacavir+lamivudine (Kivexa/Epzicom), will be discussed. Results of two large trials in ART-naïve subjects will be highlighted: 1) the HEAT trial, the first double-blinded, placebo-matched comparison of Kivexa and the combination tablet containing tenofovir+emtricitabine (Truvada), each in combination with lopinavir/ritonavir, and 2) the ARIES trial reporting results of therapy with Kivexa and atazanavir/ritonavir in subjects prescreened for the genetic allele HLA-B*5701.
Results of trials addressing long term complications of HIV therapy and the strengths and weaknesses of randomized clinical trials vs. observational cohorts will also be considered.
Merck Frosst- 5 PM to 6 PM
New Strategies in the manaement of treatment experienced patients.
The major treatment guidelines state that maximal viral suppression to non-detectability should be the goal of treatment for all HIV-infected patients, not only those naïve to antiretrovirals, but for treatment-experienced patients with resistant viruses as well. These goals are best achieved when an agent that acts on a novel target to which the patient’s virus has not been exposed can be used in a new combination. In this symposium, cases of the multi-drug experienced patient will be presented to demonstrate the principals of patient management and to outline the role of raltegravir, an integrase inhibitor, in the treatment-experienced patient population.
Anita Rachlis MD MEd FRCPC - Moderator
Professor, Department of Medicine, Division of Infectious Diseases
Sunnybrook Health Sciences Centre, University of Toronto
Presentation 1 - Clinical Update on the HIV Integrase Inhibitor Raltegravir:
Peter Sklar, MD, MPH - Speaker
Associate Director, Infectious Diseases/Vaccines Clinical Research
Merck Research Laboratories
Adjunct Assistant Professor of Medicine and Public Health, Drexel
University College of Medicine
Presentation 2 - Clinical Experience with Raltegravir:
Marianne Harris, MD, CCFPC - Speaker
AIDS Research Program, St. Paul's Hospital, Vancouver BC
Pacific Region Director, Canadian HIV Trials Network
SATURDAY, APRIL 26, 2008
Pfizer- 12:30 PM to 2 PM
Clinical role of entry inhibitors: What can we expect?
Maraviroc represents the first licensed CCR5 co-receptor antagonist from the new antiretroviral (ARV) drug class of entry inhibitors. Results of phase III clinical trials in 3-drug-class experienced patients demonstrated a powerful new agent for treatment of HIV infection. Maraviroc (BID/QD) + optimized background therapy (OBT) provided significantly superior virological control and CD4+ increases compared with placebo + OBT at 48 weeks, with no clinically relevant differences between the safety profiles of Maraviroc and placebo groups. Proven efficacy in cases of virological failure and three class ARV-drug resistance is of major benefit, while the excellent tolerability profile makes Maraviroc a particularly appealing combination partner in antiretroviral therapy. As Maraviroc is only effective against CCR5-tropic HIV-1, tropism testing is required before treatment initiation. The true clinical value of this new substance and its future role in the treatment of HIV-infection remains to be defined through further clinical data and practitioner experiences.
Dr. Juergen Rockstroh
SUNDAY, APRIL 27, 2008
Canadian Trials Network Breakfast - 7:45 AM to 9 AM
Canadian HIV Trials Network (CTN) Postdoctoral Fellows Breakfast Symposium
The CTN Postdoctoral Fellowship Programme offers career support to outstanding young clinical scientists. Since 1992 the CTN has provided 50 Fellowships for 38 individuals. Former CTN Postdoctoral Fellows during the last decade include some of Canada's leading HIV clinical investigators of today.
Update on HIV TB research in South Africa
Gonzalo G. Alvarez MD, MPH, FRCPC - Speaker
CTN Postdoctoral Fellow
Division of Respirology and Infectious Diseases University of Ottawa at The Ottawa Hospital Ottawa, ON
Antiretroviral drug resistance in non-B subtype HIV-1: An assessment of available evidence
Jorge L Martinez-Cajas, MD - Speaker
Internal Medicine, Infectious Diseases CTN Postdoctoral Fellow Hospital General Juif McGill University AIDS Centre-Lady Davis Institute
Montreal, QC
HIV and HSV-2 co-infection: An opportunity for intervention
Darrell Tan, MD FRCPC - Speaker
CTN Postdoctoral Fellow Division of Infectious Diseases University Health Network
Toronto, ON
|
